Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Glitz Pharma

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad-based pharmaceutical manufacturer focused on quality systems, local marketing, exports and contract or partnership opportunities.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Sep 2025Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
Plot 265, Industrial Triangle, Kahuta Road, Islamabad, Pakistan
Phone
+92 51 5552613; +92 51 4491310
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000571 Glitz Pharma. · Islamabad
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000571 170 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx174public portfolio records represented
REG142unique registrations represented
IDX170indexed MedInfoBase presentations
SRC4additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR170current validated price records
G73generic molecules in indexed catalogue
DF10dosage-form groups
TA13therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage96%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixGlitz PharmaShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/glitz-pharmaGenerated 24 Sep 2026Anti-infectives81 · 48%CNS & mental health42 · 25%Vitamins, minerals & nutrition15 · 9%Oncology & immunology6 · 4%Cardiovascular6 · 4%Hematology & thrombosis5 · 3%Gastrointestinal & hepatology4 · 2%Other therapeutic areas11 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioGlitz PharmaDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/glitz-pharmaGenerated 24 Sep 2026170presentationsTablet95 · 56%Capsule21 · 12%Injection16 · 9%Suspension11 · 6%Syrup10 · 6%Solution7 · 4%Other forms10 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionGlitz PharmaCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/glitz-pharmaGenerated 24 Sep 2026159comparable productsBelow peer median78 · 49%Near peer median62 · 39%Above peer median19 · 12%Company median price position-4.9%Lowest-price equivalents19Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsGlitz PharmaCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/glitz-pharmaGenerated 24 Sep 2026Nabiqasim Industries (Pvt) Ltd.,37 shared51% overlapPharmasol (Pvt) Ltd.37 shared51% overlapNeutro Pharma (Pvt.) Ltd.,37 shared51% overlapBio-Labs(Pvt) Ltd36 shared49% overlapMediate Pharmaceutical Pvt Ltd36 shared49% overlapCCL Pharmaceuticals (Pvt.) Limited35 shared48% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives81 products · 48%
CNS & mental health42 products · 25%
Vitamins, minerals & nutrition15 products · 9%
Oncology & immunology6 products · 4%
Cardiovascular6 products · 4%
Hematology & thrombosis5 products · 3%
Gastrointestinal & hepatology4 products · 2%
Pain & musculoskeletal4 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antipsychotics20 products · 12%
Third-generation cephalosporins17 products · 10%
Antiepileptics15 products · 9%
Vitamins / minerals / hematinics15 products · 9%
Antimalarials13 products · 8%
Antivirals12 products · 7%
Fluoroquinolone antibacterials12 products · 7%
Macrolide antibacterials8 products · 5%
Formulation footprint

Dosage forms

Tablet95 products
Capsule21 products
Injection16 products
Suspension11 products
Syrup10 products
Solution7 products
Cream5 products
Gel3 products
Pessary1 products
Sachet1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 QutiaQuetiapine 12presentations 100 mg, 200 mg, 25 mg, 300 mg · Tablet #2 P-ZoneCeftriaxone 6presentations 1 g, 250 mg, 500 mg · Injection #3 AerografTacrolimus 5presentations 0.5 mg, 1 mg · Capsule #4 GliximCefixime 5presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Capsule, Tablet #5 SeitamLevetiracetam 5presentations 100 mg/mL · Solution #6 ClatzClarithromycin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median7849% of comparable products
Near market median62within ±5% of median
Above market median1912% of comparable products
Lowest-price equivalents19ties included
Company median price position -4.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
ANG 0.5 mgNitroglycerin · Tablet · 3 x 10's PKR 0.65/tablet-50.0% vs market median Anafril 25 mgClomipramine · Tablet · 2 x 10's PKR 7.08/tablet-48.7% vs market median Raze 1 mgRisperidone · Tablet · 20's PKR 12.14/tablet-47.9% vs market median Sera 1.5 mgHaloperidol · Tablet · 5 x 10's PKR 0.65/tablet-47.1% vs market median Raze 2 mgRisperidone · Tablet · 20's PKR 19.73/tablet-46.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 37shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 37shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 37shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 36shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 36shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 35shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers141Distinct registrations among indexed, published, presentation-validated products only
Verified price observations170
Products with a verified price170
Products with multiple price observations0
Source records with multiple versions166
Latest portfolio source check22 Sep 2026
Latest effective price date4 Sep 2025
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

142 unique registration(s) · 170 indexed presentation(s) · 4 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
IPF Elemental iron + Folic acid 100 mg + 0.35 mg Capsule 1x10's 060199 PKR 90.55 PKR 9.06/capsule Near median
Lactogiz Syp Lactulose 3.35 mg/5 mL Syrup 120ml 040877 PKR 265.85 PKR 2.22/mL 13% below median
Lamepil Lamotrigine = 25 mg Tablet 30's 041566 PKR 607.08 PKR 20.24/tablet Near median
Lamepil Lamotrigine = 50 mg Tablet 30's 041567 PKR 809.44 PKR 26.98/tablet Near median
Lamepil Lamotrigine = 100 mg Tablet 30's 041568 PKR 1,011.80 PKR 33.73/tablet Near median
Lamiva Lamivudine 100 mg Tablet 10's 083556 PKR 502.95 PKR 50.30/tablet 12% below median
Lecetam Levetiracetam 250 mg Tablet 3 x 10 078075 PKR 1,625.34 PKR 54.18/tablet Near median
Lecetam Levetiracetam 250 mg Tablet 1 x 10 078075 PKR 541.09 PKR 54.11/tablet Near median
Lecetam Levetiracetam 500 mg Tablet 3 x 10 078076 PKR 2,695.13 PKR 89.84/tablet 7% below median
Lecetam Levetiracetam 500 mg Tablet 1 x 10 078076 PKR 898.38 PKR 89.84/tablet 7% below median
Levok Levofloxacin 250 mg Capsule 10's 066528 PKR 359.25 PKR 35.93/capsule 10% below median
Levok Levofloxacin 500 mg Capsule 10's 066529 PKR 592.77 PKR 59.28/capsule 10% below median
Lezov Levofloxacin 250 mg Tablet 1 x 10's 038542 PKR 449.06 PKR 44.91/tablet 7% below median
Lezov Levofloxacin 500 mg Tablet 1 x 10's 038543 PKR 607.14 PKR 60.71/tablet 23% below median
Lezov Levofloxacin 750 mg Tablet 1 X 7's 066432 PKR 628.69 PKR 89.81/tablet Near median
Lignocain Lidocaine 20 mg Gel 15 gm 038605 PKR 30.61 PKR 2.04/g 86% below median
Lopi-R Lopinavir + Ritonavir 200 mg + 50 mg Tablet 120's 103350 PKR 11,751.46 PKR 97.93/tablet Near median
Mogiz Moxifloxacin 400 mg Tablet 1 x 5's 038544 PKR 853.22 PKR 170.64/tablet 7% below median
Neuroglit Lithium carbonate 400 mg Tablet 100's 051137 PKR 416.51 PKR 4.17/tablet 81% below median
Nitrofurantoin Nitrofurantoin 100 mg Tablet 10 x 10's 038568 PKR 343.86 PKR 3.44/tablet 28% above median
Omeglit Omeprazole 40 mg Capsule 2 x 7's 069874 PKR 449.06 PKR 32.08/capsule 7% below median
Opinol Propranolol 40 mg Tablet 10 x 10's 038570 PKR 365.80 PKR 3.66/tablet 9% above median
Oragil Sodium chloride 2.6 g Sachet 20's 038628 PKR 496.62 PKR 24.83/sachet Near median
Oseglit Oseltamivir 75 mg Capsule 10's 103351 PKR 1,147.60 PKR 114.76/capsule Near median
P-Zone Ceftriaxone 1 g Injection 1 vial 050544 PKR 576.60 PKR 576.60/vial/unit Near median
P-Zone Ceftriaxone 500 mg Injection 1 vial 050545 PKR 305.36 PKR 305.36/vial/unit 7% below median
P-Zone Ceftriaxone 250 mg Injection 1's 050546 PKR 181.42 PKR 181.42/vial/unit 6% below median
P-Zone Ceftriaxone 250 mg Injection 1's 053658 PKR 181.42 PKR 181.42/vial/unit 6% below median
P-Zone Ceftriaxone 500 mg Injection 1's 053659 PKR 305.36 PKR 305.36/vial/unit 7% below median
P-Zone Ceftriaxone 1 g Injection 1's 053660 PKR 576.60 PKR 576.60/vial/unit Near median
Pracmol Paracetamol 500 mg Tablet 20 x 10's 038569 PKR 707.19 PKR 3.54/tablet Near median
Pracmol Paracetamol 120 mg/5 mL Suspension 60 ml 038613 PKR 62.91 PKR 1.05/mL Near median
Quinglit Hydroxychloroquine 200 mg Tablet 50's 102294 PKR 688.56 PKR 13.77/tablet Near median
Quinglit Hydroxychloroquine 200 mg Tablet 30's 102294 PKR 413.14 PKR 13.77/tablet Near median
Quinine Quinine bisulfate 300 mg Tablet 10 x 10's 038574 PKR 538.88 PKR 5.39/tablet 98% above median
Qutia Quetiapine 25 mg Tablet 30's 078077 PKR 692.34 PKR 23.08/tablet 10% above median
Qutia Quetiapine 25 mg Tablet 10's 078077 PKR 206.52 PKR 20.65/tablet Near median
Qutia Quetiapine 25 mg Tablet 20's 078077 PKR 413.04 PKR 20.65/tablet Near median
Qutia Quetiapine 100 mg Tablet 30's 078078 PKR 2,492.44 PKR 83.08/tablet 12% above median
Qutia Quetiapine 100 mg Tablet 10's 078078 PKR 743.47 PKR 74.35/tablet Near median
Qutia Quetiapine 100 mg Tablet 20's 078078 PKR 1,486.94 PKR 74.35/tablet Near median
Qutia Quetiapine 200 mg Tablet 30's 078079 PKR 2,065.23 PKR 68.84/tablet 26% below median
Qutia Quetiapine 200 mg Tablet 10's 078079 PKR 929.36 PKR 92.94/tablet 7% above median
Qutia Quetiapine 300 mg Tablet 1 x 10's 078080 PKR 1,239.14 PKR 123.91/tablet 9% below median
Qutia Quetiapine 300 mg Extended-release tablet 10's 091956 PKR 1,300.40 PKR 130.04/tablet Near median
Qutia Quetiapine 400 mg Extended-release tablet 30's 091957 PKR 4,154.07 PKR 138.47/tablet 18% below median
Qutia Quetiapine 400 mg Extended-release tablet 14's 091957 PKR 2,000.78 PKR 142.91/tablet 16% below median
Raze Risperidone 1 mg Tablet 20's 041573 PKR 242.83 PKR 12.14/tablet 48% below median
Raze Risperidone 2 mg Tablet 20's 041574 PKR 394.60 PKR 19.73/tablet 47% below median
Raze Risperidone 3 mg Tablet 10's 041575 PKR 607.08 PKR 60.71/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Glitz Pharma — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 24, 2026, from https://medinfobase.com/company/glitz-pharma/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.